T3	total-participants 650 653	140
T4	eligibility 654 687	patients with early breast cancer
T7	outcome 1165 1180	patient comfort
T9	outcome 1237 1268	Technical aspects of SLN biopsy
T10	outcome 1441 1465	SLN identification rates
T11	cv-bin-percent 1506 1510	96 %
T12	iv-bin-percent 1524 1528	90 %
T13	iv-bin-percent 1551 1555	97 %
T14	iv-bin-percent 1592 1596	90 %
T15	outcome 1644 1675	SLN 2/SLN 1 ex vivo count ratio
T16	outcome 1685 1708	number of SLNs detected
T2	outcome 1308 1340	time from injection to operation
T17	outcome 1342 1359	first SLN (SLN 1)
T18	outcome 1380 1394	ex vivo counts
T19	outcome 1420 1439	axillary bed counts
T5	control 793 800	control
T6	outcome 1182 1213	Overall SLN identification rate
T1	intervention 28 70	1 % lidocaine to technetium sulfur colloid
T8	control 841 862	topical placebo cream
